Evaluate the probability of disease progression in a Crohn’s disease patient by providing a personal serogenetic profile.
The PROMETHEUS® Crohn’s Prognostic combines proprietary serologic (anti-CBir1, anti-OMPC, DNAse sensitive pANCA) and genetic (NOD2 variants SNPs 8,12,13) markers in an innovative blood test that quantifies a patients individual probability of developing disease complications over time. The objective information from the test may allow physicians to stratify patients, assist in optimizing management strategies and may be used in risk/benefit discussions.
Sample insurance correspondence for PROMETHEUS® Crohn’s Prognostic
- These tests have not been cleared or approved by the US FDA. The tests are used for clinical purposes and should not be regarded as investigational or for research. Prometheus Biosciences is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing and is accredited by the College of American Pathologists (CAP).
- This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.